Literature DB >> 7569458

[Comparison of 2 treatment schemes to eradicate Helicobacter pylori].

P Hoffenberg1, V Reyes, L Contreras, M Giglio, P Ossa, J C Weitz.   

Abstract

INTRODUCTION: Anti secretory drugs, antimicrobials and bismuth salts are used with variable success to eradicate Helicobacter pylori. AIM: To assess the effectiveness and rates of reinfection of two therapeutic modalities H pylori infection in adult patients with duodenal ulcer or non ulcer dyspepsia.
METHODS: During upper gastrointestinal endoscopy, 5 antral and 2 fundic biopsies were obtained and sent for microbiological and anatomopathological study. Patients infected with Helicobacter pylori were randomly assigned to receive during two weeks omeprazole 20 mg od plus amoxicillin 500 mg tid (group A) or bismuth subsalicylate 260 mg bid, metronidazole 250 mg tid and amoxicillin 500 mg tid (group B). A new endoscopy with antral and fundic biopsies was performed to all patients four weeks after discontinuing treatment and six months later to those in whom H pylori was eradicated.
RESULTS: Eighty patients (40 in each treatment group) completed the treatment and follow up. H pylori was eradicated in 22 patients of group A (55%) and 28 of group B (70%). Minor adverse effects were reported by 5 patients in group A (12%) and 11 in group B (27.5%). Six months later, reinfection was documented in 12 patients of group A and 8 of group B (54% and 30% of those with successful treatment respectively). Ten of twenty five patients with duodenal ulcer had reinfections, but there was only one ulcer relapse.
CONCLUSIONS: These two treatment modalities have similar results.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7569458

Source DB:  PubMed          Journal:  Rev Med Chil        ISSN: 0034-9887            Impact factor:   0.553


  5 in total

Review 1.  Recurrence of Helicobacter pylori infection after successful eradication: nature and possible causes.

Authors:  H X Xia; N J Talley; C T Keane; C A O'Morain
Journal:  Dig Dis Sci       Date:  1997-09       Impact factor: 3.199

Review 2.  A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy.

Authors:  U Peitz; A Hackelsberger; P Malfertheiner
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

Review 3.  Optimal therapy for Helicobacter pylori infections.

Authors:  Emiko Rimbara; Lori A Fischbach; David Y Graham
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 46.802

4.  Presentation and outcome of chronic kidney disease in Italian and immigrant citizens: results from the Emilia-Romagna PIRP project.

Authors:  Dino Gibertoni; Leonardo Mammana; Giulia Gherardi; Erica Baschieri; Francesco Minora; Antonio Santoro
Journal:  J Nephrol       Date:  2021-02-17       Impact factor: 3.902

5.  Reinfection after successful eradication of Helicobacter pylori in three different populations in Alaska.

Authors:  M G Bruce; D L Bruden; J M Morris; A L Reasonover; F Sacco; D Hurlburt; T W Hennessy; J Gove; A Parkinson; G Sahagun; P Davis; J Klejka; B J McMahon
Journal:  Epidemiol Infect       Date:  2014-07-28       Impact factor: 4.434

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.